Market Overview

Esperion Shares Plunge After Cholesterol-Lowering Drug's Phase 3 Results Stir Safety Concerns

Share:
Esperion Shares Plunge After Cholesterol-Lowering Drug's Phase 3 Results Stir Safety Concerns

Esperion Therapeutics Inc (NASDAQ: ESPR) shares are in free fall Wednesday after the company reported first-quarter results and gave an update on its bempedoic acid franchise development program.

The stock was down 26.25 percent to $51.99 at time of publication.

What Happened

Esperion, which specializes in developing therapies for patients with elevated LDL cholesterol, reported a wider-than-expected loss of $1.73 per share in Q1 against a consensus estimate of $1.56 — although the loss was narrower than a year ago.

The company announced positive top-line results from its second pivotal Phase 3 study that evaluated the long-term safety of bempedoic acid at a 180 mg dose. 

The pipeline candidate achieved additional 20 percent on-treatment LDL cholesterol lowering at week 12, and additional hsCRP reduction of 22 percent on background maximally tolerated statin therapy.

Although adverse events and rates of serious adverse events were comparable between the treatment group and placebo, the treatment group saw 13 deaths compared to two in the control group.

Why It's Important

The results are important, as there are competitors in the race for a breakthrough for the indication, including Regeneron Pharmaceuticals Inc (NASDAQ: REGN), Amgen, Inc. (NASDAQ: AMGN), Novartis AG (ADR) (NYSE: NVS) and others. 

"ESPR Study 1 demonstrates clean safety profile and robust efficacy with early signal of benefit in adjudicated CV events," JMP Securities said of the data. 

"We firmly agree with management's perspective that the fatalities seen in Study 1 were not related to study drug (0.9 percent on bempedoic acid vs. 0.3 percent on placebo)."

What's Next

Esperion said it expects to submit a NDA for bempedoic acid and the combo pill no later than the first quarter of 2019. The company also intends to submit marketing authorization applications to the European Medicines Agency no later than the second quarter of 2019.

Related Links:

Benzinga's Daily Biotech Pulse: SIGA Rallies On FDA Panel Backing, Rigel And Gilead React To Earnings

The Week Ahead In Biotech: PDUFA Dates, Clinical Trials, Merck And Pfizer Earnings On Tap

Latest Ratings for ESPR

DateFirmActionFromTo
May 2020JefferiesMaintainsBuy
Apr 2020Northland Capital MarketsMaintainsMarket Perform
Apr 2020B of A SecuritiesInitiates Coverage OnBuy

View More Analyst Ratings for ESPR
View the Latest Analyst Ratings

 

Related Articles (ESPR)

View Comments and Join the Discussion!

Posted-In: JMP SecuritiesBiotech Earnings News Top Stories Analyst Ratings Trading Ideas Best of Benzinga

Latest Ratings

StockFirmActionPT
OZKMorgan StanleyMaintains29.0
APTVCredit SuisseMaintains91.0
ADTMorgan StanleyMaintains17.0
TXRHRaymond JamesMaintains67.5
RNGRaymond JamesMaintains355.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com